Angiogenesis: trabeculectomy and bevacizumab.
The use of bevacizumab for the treatment of proliferative diabetic retinopathy, neovascular glaucoma, neovascular age related macular degeneration, and cystoid macular edema has been extensively reported upon. From the published case reports available, bevacizumab may be a useful adjunct to the trabeculectomy procedure.
Jue
Andrea
A
Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000963:Antimetabolites / Q000627:therapeutic use; D000068258:Bevacizumab; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007430:Intraoperative Care; D016685:Mitomycin / Q000627:therapeutic use; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D011182:Postoperative Care; D011300:Preoperative Care; D014130:Trabeculectomy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000963:Antimetabolites; D019384:Nucleic Acid Synthesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D016685:Mitomycin; D005472:Fluorouracil